CN106414445B - 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用 - Google Patents

化合物及其在扩增造血干细胞和/或造血祖细胞中的应用 Download PDF

Info

Publication number
CN106414445B
CN106414445B CN201580026051.4A CN201580026051A CN106414445B CN 106414445 B CN106414445 B CN 106414445B CN 201580026051 A CN201580026051 A CN 201580026051A CN 106414445 B CN106414445 B CN 106414445B
Authority
CN
China
Prior art keywords
mmol
alkyl
compound
cells
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580026051.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106414445A (zh
Inventor
G·索瓦若
Y·加罗
S·金格拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Priority to CN202010516927.6A priority Critical patent/CN111620870B/zh
Publication of CN106414445A publication Critical patent/CN106414445A/zh
Application granted granted Critical
Publication of CN106414445B publication Critical patent/CN106414445B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201580026051.4A 2014-04-22 2015-04-21 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用 Active CN106414445B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010516927.6A CN111620870B (zh) 2014-04-22 2015-04-21 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982445P 2014-04-22 2014-04-22
US61/982,445 2014-04-22
PCT/CA2015/050330 WO2015161373A1 (en) 2014-04-22 2015-04-21 Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010516927.6A Division CN111620870B (zh) 2014-04-22 2015-04-21 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用

Publications (2)

Publication Number Publication Date
CN106414445A CN106414445A (zh) 2017-02-15
CN106414445B true CN106414445B (zh) 2020-07-03

Family

ID=54331531

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580026051.4A Active CN106414445B (zh) 2014-04-22 2015-04-21 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用
CN202010516927.6A Active CN111620870B (zh) 2014-04-22 2015-04-21 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010516927.6A Active CN111620870B (zh) 2014-04-22 2015-04-21 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用

Country Status (7)

Country Link
US (1) US10647718B2 (https=)
EP (1) EP3134409B1 (https=)
JP (1) JP6762233B2 (https=)
CN (2) CN106414445B (https=)
CA (1) CA2946446C (https=)
ES (1) ES2788977T3 (https=)
WO (1) WO2015161373A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107208111B (zh) 2014-09-18 2021-07-06 蒙特利尔大学 用于增强病毒基因转移至人造血细胞的化合物和方法
CA3024273A1 (en) * 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
KR102522572B1 (ko) * 2016-08-18 2023-04-17 내셔널 유니버시티 오브 싱가포르 조혈 줄기 및 전구 세포의 생성, 증식 및 분화를 위한 치환된 아졸 유도체
CN106727541A (zh) * 2017-02-20 2017-05-31 刘金涛 一种治疗耳肿胀的药物组合物
CN107353288B (zh) * 2017-06-23 2019-10-18 吉林大学 4-乙胺(2-羧基)-9H-嘧啶并[4,5-b]吲哚及其制备方法
AU2018354418B2 (en) * 2017-10-27 2025-09-11 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
US12011460B2 (en) 2018-02-20 2024-06-18 Universite De Montreal Expansion of NK and DC cells in vivo mediating immune response
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
WO2020106059A1 (ko) * 2018-11-21 2020-05-28 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
AU2020409437A1 (en) * 2019-12-18 2022-07-14 Universite De Montreal Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds
MX2022008715A (es) * 2020-01-24 2022-07-21 Univ Tokyo Medio libre de suero y metodo de cultivo adecuado para el cultivo de celulas sanguineas, incluidas celulas madre hematopoyeticas humanas.
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US11851430B1 (en) * 2023-09-06 2023-12-26 King Faisal University Pyrido[4,3-B]indole-7-carboxylic acid compounds as CK2 inhibitors
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
CN120157613A (zh) * 2023-12-15 2025-06-17 山东诚创蓝海医药科技有限公司 多拉韦林中间体及其应用和合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007061764A2 (en) * 2005-11-22 2007-05-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2013110198A1 (en) * 2012-01-27 2013-08-01 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595701B1 (fr) 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
JP2002529502A (ja) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
EP1213965B1 (en) 1999-09-10 2006-01-18 Smithkline Beecham Corporation Thrombopoietin mimetics
ATE350044T1 (de) 1999-09-24 2007-01-15 Smithkline Beecham Corp Thrombopoietinmimetika
WO2001034585A1 (en) 1999-11-05 2001-05-17 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
AU2079901A (en) 1999-12-06 2001-06-12 Smithkline Beecham Corporation Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
WO2002049413A2 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1442039A1 (en) * 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1581527A4 (en) 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
ATE478863T1 (de) 2005-07-14 2010-09-15 Irm Llc Heterotetracyclische verbindungen als tpo- mimetica
US7816542B2 (en) 2005-08-15 2010-10-19 Irm Llc Compounds and compositions as TPO mimetics
KR20090021217A (ko) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제
JP2008050355A (ja) * 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
JP2010525836A (ja) * 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のｅｘｖｉｖｏ増殖
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN101423517B (zh) * 2008-11-28 2011-09-14 浙江大学 γ-咔啉类衍生物及其制备方法和用途
JP2010193879A (ja) 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
US9198900B2 (en) 2011-11-10 2015-12-01 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment of peritoneal injury using JAK inhibitors
CN107011342A (zh) 2012-05-22 2017-08-04 伊莱利利公司 用于检测神经功能障碍的基于咔啉和咔唑的成像剂
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007061764A2 (en) * 2005-11-22 2007-05-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2013110198A1 (en) * 2012-01-27 2013-08-01 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEW HETEROCYCLIC RING SYSTEMS : THE SYNTHESES OF 2H,3H,7H-IMIDAZ0[1",2":1,2]PYRID0[4,3-b]lNDOLES AND 2H,3H,4H,8H-PYRIMIDO[l",2":1,2]PYRIDO[4,3-b]INDOLES;Kazuho Harada et al.;《Heterocycles》;19941231;第38卷(第8期);第1868页 *

Also Published As

Publication number Publication date
US20170037047A1 (en) 2017-02-09
EP3134409A1 (en) 2017-03-01
EP3134409B1 (en) 2020-02-12
CN111620870B (zh) 2023-01-03
ES2788977T3 (es) 2020-10-23
EP3134409A4 (en) 2017-10-04
CN111620870A (zh) 2020-09-04
WO2015161373A1 (en) 2015-10-29
JP6762233B2 (ja) 2020-09-30
JP2017513897A (ja) 2017-06-01
CA2946446A1 (en) 2015-10-29
US10647718B2 (en) 2020-05-12
CA2946446C (en) 2020-11-03
CN106414445A (zh) 2017-02-15

Similar Documents

Publication Publication Date Title
CN106414445B (zh) 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用
CN104144931B (zh) 嘧啶并[4,5‑b]吲哚衍生物及其在造血干细胞的扩增中的应用
TWI784207B (zh) 作為nav1.8 抑制劑之2-胺基-n-雜芳基-菸鹼醯胺
JP2022110135A (ja) Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン
TWI662039B (zh) 用於誘發軟骨生成之化合物及組合物
WO2024046370A1 (zh) 作为kras抑制剂的杂环化合物，及其制备和治疗用途
JP2022542396A (ja) Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
WO2010119875A1 (ja) 縮合ピロロピリジン誘導体
CN102933583A (zh) 作为jak抑制剂的杂芳基咪唑酮衍生物
JP6026525B2 (ja) 置換６−アザ−イソインドリン−１−オン誘導体
CN111417640A (zh) 化合物及其在干细胞和/或祖细胞扩增中的应用
JP2009513678A (ja) 化合物
CN117486888A (zh) 三环类化合物及其用途
WO2022083560A1 (zh) Tyk2选择性抑制剂及其用途
CN114341125A (zh) Trex1调节剂
JP2025528119A (ja) Ｊａｋ２阻害剤としての複素環式アミド及び尿素化合物
HK40103741A (zh) 三环类化合物及其用途
CN118201928A (zh) 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑
HK40105446A (zh) 三环类化合物及其用途
HK40060604B (zh) 三环类化合物及其用途
HK1203945B (en) Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
TW201215606A (en) Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
HK1227845B (zh) 4-氨基-咪唑并喹啉化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant